Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

How do i prepare for my first spravato treatment?

How do I prepare for my first Spravato treatment?

Spravato (esketamine) is a nasal spray for treatment-resistant depression. It must be administered in a certified medical setting under medical supervision.

What should I do the day of my appointment?

Plan for a 2-3 hour visit. Bring someone to drive you home because Spravato can cause dizziness and sedation. Do not drive or operate machinery for the rest of the day. Eat a light meal beforehand to help reduce nausea, but avoid heavy meals.

What medications and substances should I avoid?

Tell your doctor about all medications and drinks you consume. Avoid alcohol on the day of treatment. Avoid taking benzodiazepines or opioids unless your doctor approves. Check with your doctor if you take blood pressure medication.

How does the treatment feel?

During treatment you may experience temporary side effects such as increased blood pressure, dizziness, or a feeling of disconnection. These effects peak around 40 minutes after administration and fade within 1-2 hours. Your blood pressure will be monitored regularly during the session.

What happens after I finish the session?

You stay in the clinic until your side effects stabilise. The doctor will release you only once you are stable. You must arrange transportation home. You cannot drive yourself.

When does the Spravato patent expire?

The patent for Spravato expires in 2034. Biosimilars or generics are unlikely to enter the market until after that date.



Other Questions About First :

Do i need a first dose observation for gilenya? Can you name the first cancer keytruda was approved to treat? When did you first notice your vascepa allergy symptoms? Should i consult a doctor first? Are first trimester weeks critical for alcohol exposure? What kind of cancer received the first fda approval for keytruda? What was the first cancer where keytruda showed effectiveness?